Saturday, November 2, 2024

Lower Back Pain Treatment Advances with New ICD-10 Code for Multifidus Muscle Dysfunction and ReActiv8 Therapy

Similar articles

Subscribe Weekly Market Access News

* indicates required

Key Takeaways

  • The U.S. CDC has introduced a new ICD-10-CM diagnostic code, M62.85, specifically for multifidus muscle dysfunction in the lumbar region, recognizing its role in chronic lower back pain.
  • Mainstay Medical’s ReActiv8® Restorative Neurostimulationâ„¢ is the only FDA-approved treatment designed to restore multifidus muscle function, providing relief for patients with intractable chronic low back pain.
  • The new diagnostic code provides healthcare professionals with a clearer pathway for diagnosing and treating multifidus dysfunction, potentially improving outcomes for patients who have not found relief through traditional therapies.

Mainstay Medical has announced a significant development in the recognition and treatment of chronic lower back pain, with the introduction of a new ICD-10-CM diagnostic code for multifidus muscle dysfunction. The U.S. Centers for Disease Control and Prevention (CDC) has assigned the code M62.85: dysfunction of the multifidus muscles, lumbar region, which came into effect on October 1, 2024. This new code acknowledges the specific role of multifidus muscle dysfunction as a key factor in chronic lower back pain, providing healthcare professionals with a clearer diagnostic pathway for this condition.

Multifidus dysfunction occurs when the brain reduces neural input to the multifidus muscle in response to an acute injury in the lower back. This results in decreased muscle activity, leading to instability of the lumbar spine, joint overload, and, over time, chronic pain. The multifidus muscle plays a crucial role as a primary stabilizer of the lower spine, and when its function is compromised, it can exacerbate lower back issues, contributing to persistent and often debilitating pain.

To address this dysfunction, Mainstay Medical has developed the ReActiv8® Restorative Neurostimulation™ system, which is specifically designed to deliver electrical stimulation to the nerves that activate the multifidus muscle. This neurostimulation helps restore the muscle’s function and assists in the recovery process for patients suffering from intractable chronic lower back pain. ReActiv8 is currently the only FDA-approved treatment for chronic lower back pain directly associated with multifidus muscle dysfunction, providing a unique solution for a previously under-recognized problem.

CDC’s Recognition of Multifidus Muscle Dysfunction Marks a Milestone in Chronic Lower Back Pain Treatment with ReActiv8

Jason Hannon, CEO of Mainstay Medical, expressed the importance of this new diagnostic code: “The CDC’s recognition of multifidus muscle dysfunction as a significant contributor to chronic lower back pain is a critical step forward. It provides clinicians with a more specific diagnostic tool for identifying the underlying cause of pain in patients for whom traditional treatments have failed. Multifidus dysfunction is a unique pathology that doesn’t respond to palliative approaches, and the new code reflects this distinction.”

The introduction of this ICD-10-CM code marks a milestone in the field of spine health, allowing healthcare providers to better identify and treat multifidus dysfunction. By addressing the root cause of the dysfunction, physicians can offer more targeted treatments, potentially improving outcomes for patients who have struggled with chronic pain for years.

ReActiv8 is an innovative, implantable medical device developed to treat adults with chronic low back pain that has proven resistant to other treatments, such as pain medication and physical therapy. It is specifically designed for patients suffering from multifidus muscle dysfunction, a condition that can be diagnosed through imaging or physiological tests. This device offers a new therapeutic option for patients who are not candidates for spinal surgery and have exhausted conventional treatment methods.

Lower Back Pain

ReActiv8 Gains Global Recognition as New ICD-10 Code Enhances Diagnosis and Treatment of Chronic Lower Back Pain

ReActiv8 works by stimulating the nerves responsible for activating the multifidus muscle, helping to restore muscle control and improve spinal stability. Clinical trials have shown significant improvements in pain reduction and functional recovery for patients treated with ReActiv8. The device is currently approved in several key markets, including the European Economic Area, Australia, the United Kingdom, and the United States, where it has received FDA approval for the treatment of chronic low back pain.

You can follow our news on our Telegram, LinkedIn and Youtube accounts.

The inclusion of multifidus muscle dysfunction in the ICD-10-CM code system underscores the growing recognition of the muscle’s role in chronic lower back pain. As more patients and healthcare providers become aware of this condition, the hope is that the ReActiv8 system will offer a new pathway to relief for individuals who have struggled with chronic pain for years without effective solutions.

The introduction of this new diagnostic code is expected to streamline the process of identifying eligible patients, allowing for earlier and more accurate diagnosis and leading to timely and effective treatment with ReActiv8. As Mainstay Medical continues to expand the availability of this treatment, the company remains committed to improving the quality of life for patients suffering from chronic low back pain across the globe.

 

Resource: Mainstay Medical, October 03, 2024


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article